Development of a VesiVax HIV Vaccine Formulation

NIH RePORTER · NIH · N44 · $1,994,571 · view on reporter.nih.gov ↗

Abstract

Particle-based Co-delivery of HIV immunogens as Next-generation HIV Vaccines: Tailored immunogens (such as Envs, monomers, native and/or native-like trimers, nucleic acids/RNA such as mRNAs, self-amplifying RNAs) combined with an effective multivalent antigenic display on nanoparticles for delivery may provide a strategy to promote strong and long-lived neutralizing antibody responses against HIV and direct affinity maturation toward HIV neutralizing antibodies. The objective of this contract is to evaluate the different co-delivery methods of a model HIV antigen using the VesiVax liposomal platform.

Key facts

NIH application ID
10653678
Project number
75N93021C00027-P00003-9999-1
Recipient
MOLECULAR EXPRESS, INC.
Principal Investigator
SAM ON HO
Activity code
N44
Funding institute
NIH
Fiscal year
2022
Award amount
$1,994,571
Award type
Project period
2022-08-01 → 2024-07-31